Elixir Clinical Research recently announced that Mr. Jerry Weaver, with over 30 years of biopharmaceutical R&D experience, has joined the company as Vice President and Head of U.S. Operations. Mr. Jerry Weaver will be responsible for the operations and expansion of the company’s business in the United States after he joins Elixir Clinical Research. Technology-led service and talent-supported development along with the joining of Mr. Jerry Weaver will enable Elixir Clinical Research to enter into a new chapter for the deployment of globalized R&D and the construction of international multi-center clinical service capability.

Mr. Jerry Weaver

Mr. Jerry Weaver graduated from the University of Iowa with a master’s degree in statistics and received his master’s degree in economics and business administration from Truman State University. Prior to joining Elixir Clinical Research, Mr. Jerry Weaver worked for top global pharmaceutical companies including Bristol-Myers Squibb, Celgene, Novartis, and Pfizer. With over 30 years of global new drug development and team management experience, he has built international professional statistical teams, trained a large number of international talents in the new drug development, provided drug development guidance to cross-functional teams, helped employee develop their skills, and built a company culture with an atmosphere of welcoming, resilience, and innovation.

There are two main aspects in the process of adapting to the job, namely learning SAS programming knowledge and familiarizing yourself with the workflow. Years of study have taught us that no matter what we learn, systematization is very important. After mastering the overall framework, you can add details to this framework through daily work and accumulation to enrich and complete the knowledge system.

Mr. Jerry Weaver has been deeply involved in the new drug development in multiple therapeutic areas, including neuroscience, cardiovascular, anti-infectives, immunology, and hematology/oncology, and has participated in and supported numerous international multi-center clinical development projects involving phase 1-3 clinical trials, post-marketing, non-clinical/pre-clinical, and drug license introduction, and has a track record of 6 successful new drug submissions.

Mr. Liedong Xu, General Manager of Elixir Clinical Research said:

“It is a great pleasure to have Mr. Jerry Weaver join Elixir Clinical Research as Head of U.S. Operations. Mr. Jerry Weaver has extensive successful experience in drug development, including clinical development planning, regulatory authority connection, clinical trial design and analysis, statistical strategy consulting, resource planning and management. The joining of Mr. Jerry Weaver is an important manifestation of Elixir’s adherence to technology-led services and talent-supported development. In the long journey to build its international multi-center clinical service capabilities, Elixir Clinical Research will continue to give its expertise into full play - technological innovation. With self-developed data analysis and statistical programming tools, digital standardized project management system and remote monitoring services, and continuous integration with international high-quality and high-standard new drug development technologies, the joining of Mr. Jerry Weaver will further promote Elixir Clinical Research’s global delivery capabilities and continue to steadily improve and expand the company to become a technology-enabled clinical full service company with international standards.”

Mr. Jerry Weaver said:

“The rapid new drug development in China is recognized worldwide. Clinical new drug development and regulatory review in China have undergone significant changes along with the reform of the regulatory system, while a number of digitally intelligent and innovative solutions are gradually penetrating the pharmaceutical industry, making the new drug development flourish and thrive. Elixir Clinical Research is a technology-enabled full service clinic CRO company. I am honored to join this innovative team with an international vision. Elixir Clinical Research has independent R&D capabilities, advanced digital system tools, artificial intelligence technology and extensive application of decentralized clinical trials, combined with world-class innovative statistical thinking and solid clinical development knowledge. I look forward to pioneering innovation with the company in the future, accelerating the speed of global new drug development, improving the quality of international service delivery and bringing more innovative treatment solutions to patients worldwide.”